Adding Palifosfamide to Doxorubicin Fails to Improve PFS in Sarcoma

Share this content:
The addition of palifosfamide to doxorubicin did not significantly improve progression-free or overall survival.
The addition of palifosfamide to doxorubicin did not significantly improve progression-free or overall survival.

The addition of palifosfamide to doxorubicin did not significantly improve progression-free or overall survival, compared with doxorubicin plus placebo, among patients with metastatic soft tissue sarcoma, according to a study published in the Journal of Clinical Oncology.1

Palifosfamide, the active metabolite of ifosfamide, does not require prodrug formation, thereby bypassing the formation of toxic metabolites observed with the metabolism of ifosfamide and cyclophosphamide.

For the international, phase 3 PICASSO trial, investigators enrolled 447 patients with metastatic soft tissue sarcoma who had received no prior systemic therapy, and randomly assigned them 1:1 to receive doxorubicin plus palifosfamide or placebo.

Median progression-free survival was 6.0 months with palifosfamide and 5.2 months with doxorubicin (hazard ratio, 0.86; 95% CI, 0.68-1.08; P = .19).

Median overall survival was 15.9 months for doxorubicin plus palifosfamide, versus 16.9 months for doxorubicin plus placebo (hazard ratio, 1.05; 95% CI, 0.79-1.39; P = .74).

RELATED: Biosimilar G-CSF Effective in Preventing Febrile Neutropenia in Sarcoma

Palifosfamide treatment was associated with a higher rate of grade 3 to 4 adverse events, including a higher rate of febrile neutropenia.                    

Reference

  1. Ryan CW, Merimsky O, Agulnik M, et al. PICASSO III: A phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J Clin Oncol. 2016 Sep 12. doi: 10.1200/JCO.2016.67.6684 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs